Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Neuro-oncology

Late neurocognitive decline after radiotherapy for low-grade glioma

Nature Reviews Neurology volume 5, pages 646–647 (2009)Cite this article

Radiotherapy is administered to most patients with low-grade glioma. A well-designed, retrospective study assessed neurocognitive function in patients who had received radiotherapy for low-grade gliomas versus those who had not. Cognitive function did not differ markedly between groups after 6 years, but by 12 years this feature was worse in the group that received radiotherapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Louis, D. N. et al. WHO Classification of Tumors of the Central Nervous System, 4th edn (International Agency for Research on Cancer, Lyon, 2007).

    Google Scholar 

  2. Douw, L. et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 8, 810–818 (2009).

    Article  Google Scholar 

  3. Klein, M. et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360, 1361–1368 (2002).

    Article  CAS  Google Scholar 

  4. van den Bent, M. J. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985–990 (2005).

    Article  CAS  Google Scholar 

  5. Pignatti, F. et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J. Clin. Oncol. 20, 2076–2084 (2002).

    Article  Google Scholar 

  6. Olson, J. D., Riedel, E. & DeAngelis, L. M. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54, 1442–1448 (2000).

    Article  CAS  Google Scholar 

  7. Mariani, L. et al. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J. Clin. Oncol. 24, 4758–4763 (2006).

    Article  CAS  Google Scholar 

  8. Smith, J. S. et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol. 26, 1338–1345 (2008).

    Article  Google Scholar 

  9. DeAngelis, L. M., Delattre, J. Y. & Posner, J. B. Radiation-induced dementia in patients cured of brain metastases. Neurology 39, 789–796 (1989).

    Article  CAS  Google Scholar 

  10. Patchell, R. A. et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485–1489 (1998).

    Article  CAS  Google Scholar 

  11. Lassman, A. B. et al. International retrospective study of 1,000+ adults with anaplastic oligodendroglial tumors [Abstract 283]. Neuro. Oncol. 11, 629 (2009).

    Google Scholar 

Download references

Acknowledgements

The authors thank Judy Lampron for her expert editorial assistance.

Author information

Authors and Affiliations

  1. Department of Neurology and Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Mustafa Khasraw & Andrew B. Lassman

Authors
  1. Mustafa Khasraw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew B. Lassman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew B. Lassman.

Ethics declarations

Competing interests

Dr. Lassman declares associations with the following companies: Bristol–Myers Squibb, Cephalon, Eisai, Enzon Pharmaceuticals, Genentech, ImClone Systems, Keryx Biopharmaceuticals, Schering–Plough and Sigma–Tau Pharmaceuticals. Dr. Khasraw declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khasraw, M., Lassman, A. Late neurocognitive decline after radiotherapy for low-grade glioma. Nat Rev Neurol 5, 646–647 (2009). https://doi.org/10.1038/nrneurol.2009.194

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2009.194

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing